Table of Contents
Chemotherapy Research and Practice
Volume 2014 (2014), Article ID 570241, 9 pages
http://dx.doi.org/10.1155/2014/570241
Research Article

Ferric Carboxymaltose-Mediated Attenuation of Doxorubicin-Induced Cardiotoxicity in an Iron Deficiency Rat Model

1Hospital Alemán, Laboratory of Experimental Medicine, School of Medicine, Avenue Pueyrredon 1640, 1118 Buenos Aires, Argentina
2Instituto de Química y Fisicoquímica Biológica (UBA-CONICET), Facultad de Farmacia y Bioquímica, University of Buenos Aires, Buenos Aires, Argentina
3Vifor (International) AG, Rechenstrasse 37, 9014 St. Gallen, Switzerland
4Vifor Pharma, 1203-4464 Markham Street, Victoria, BC, Canada V8Z 7X8

Received 25 December 2013; Accepted 25 March 2014; Published 30 April 2014

Academic Editor: H. J. Schmoll

Copyright © 2014 Jorge Eduardo Toblli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Smith, V. R. Cornelius, C. J. Plummer et al., “Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials,” BMC Cancer, vol. 10, article 337, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Barry, J. A. Alvarez, R. E. Scully, T. L. Miller, and S. E. Lipshultz, “Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management,” Expert Opinion on Pharmacotherapy, vol. 8, no. 8, pp. 1039–1058, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Minotti, G. Cairo, and E. Monti, “Role of iron in anthracycline cardiotoxicity: new tunes for an old song?” FASEB Journal, vol. 13, no. 2, pp. 199–212, 1999. View at Google Scholar · View at Scopus
  4. C. Myers, “The role of iron in doxorubicin-induced cardiomyopathy,” Seminars in Oncology, vol. 25, no. 4, supplement 10, pp. 10–14, 1998. View at Google Scholar · View at Scopus
  5. H. G. Keizer, H. M. Pinedo, G. J. Schuurhuis, and H. Joenje, “Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity,” Pharmacology and Therapeutics, vol. 47, no. 2, pp. 219–231, 1990. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Ludwig, S. Van Belle, P. Barrett-Lee et al., “The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients,” European Journal of Cancer, vol. 40, no. 15, pp. 2293–2306, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Ludwig, E. Muldur, G. Endler, and W. Hubl, “Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia,” Annals of Oncology, vol. 24, no. 7, pp. 1886–1892, 2013. View at Publisher · View at Google Scholar
  8. National Comprehensive Cancer Network, NCCN Practice Guidelines in Oncology; Cancer and Chemotherapy-Induced Anemia—Version 2.2014, 2014, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive.
  9. M. Aapro, A. Osterborg, P. Gascon, H. Ludwig, and Y. Beguin, “Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of I.V.Iron,” Annals of Oncology, vol. 23, no. 8, pp. 1954–1962, 2012. View at Google Scholar
  10. D. Cella, J. Kallich, A. McDermott, and X. Xu, “The longitudinal of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomised clinical trials,” Annals of Oncology, vol. 15, no. 6, pp. 979–986, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. J. Caro, M. Salas, A. Ward, and G. Goss, “Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review,” Cancer, vol. 91, no. 12, pp. 2214–2221, 2001. View at Google Scholar
  12. C. A. Hudis, S. Van Belle, J. Chang, and K. Muenstedt, “rHuEPO and treatment outcomes: the clinical experience,” Oncologist, vol. 9, no. 5, pp. 55–69, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Dong, X. Zhang, B. Culver, H. G. Chew Jr., R. O. Kelley, and J. Ren, “Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: Involvement of nitric oxide synthase and protein tyrosine nitration,” Clinical Science, vol. 109, no. 3, pp. 277–286, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Geisser and S. Burckhardt, “The pharmacokinetics and pharmacodynamics of iron preparations,” Pharmaceutics, vol. 3, no. 1, pp. 12–33, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. E. H. Herman, A. N. El-Hage, V. J. Ferrans, and B. Ardalan, “Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats,” Toxicology and Applied Pharmacology, vol. 78, no. 2, pp. 202–214, 1985. View at Google Scholar · View at Scopus
  16. E. H. Herman and V. J. Ferrans, “Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity,” Seminars in Oncology, vol. 25, no. 4, supplement 10, pp. 15–21, 1998. View at Google Scholar · View at Scopus
  17. J. E. Toblli, M. G. Ferrini, G. Cao, D. Vernet, M. Angerosa, and N. F. Gonzalez-Cadavid, “Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus,” Nephrology Dialysis Transplantation, vol. 24, no. 8, pp. 2384–2391, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. E. Toblli, G. Cao, C. Rivas et al., “Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats,” Journal of Hypertension, vol. 28, no. 5, pp. 1007–1019, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. E. Toblli, G. Cao, and M. Angerosa, “Comparison of early gastrointestinal tract and liver toxicity of the originator iron polymaltose complex (IPC) and an IPC similar preparation in non-anemic rats,” International Journal of Clinical Pharmacology and Therapeutics, vol. 50, no. 8, pp. 573–583, 2012. View at Google Scholar
  20. J. E. Toblli, G. Cao, L. Oliveri, and M. Angerosa, “Differences between original intravenous iron sucrose and iron sucrose similar preparations,” Drug Research, vol. 59, no. 4, pp. 176–190, 2009. View at Google Scholar · View at Scopus
  21. J. E. Toblli, G. Cao, J. F. Giani, M. C. Muñoz, M. Angerosa, and F. P. Dominici, “Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats,” Journal of Hypertension, vol. 29, no. 8, pp. 1613–1623, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J. B. Owen and D. A. Butterfield, “Measurement of oxidized/reduced glutathione ratio,” Methods in Molecular Biology, vol. 648, pp. 269–277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Chance and A. C. Maehly, “Assay of catalase and peroxidase,” in Methods in Enzymology, S. P. Colowick and N. O. Kaplan, Eds., pp. 764–775, Academic Press, New York, NY, USA, 1955. View at Google Scholar
  24. M. L. Schuman, M. S. Landa, J. E. Toblli et al., “Cardiac thyrotropin-releasing hormone mediates left ventricular hypertrophy in spontaneously hypertensive rats,” Hypertension, vol. 57, no. 1, pp. 103–109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. J. E. Toblli, G. Cao, C. Rivas, and H. Kulaksiz, “Heart and iron deficiency anaemia in rats with renal insufficiency: the role of hepcidin,” Nephrology, vol. 13, no. 7, pp. 636–645, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. A. Doggrell and L. Brown, “Rat models of hypertension, cardiac hypertrophy and failure,” Cardiovascular Research, vol. 39, no. 1, pp. 89–105, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. E. A. Jankowska, H. S. von, S. D. Anker, I. C. Macdougall, and P. Ponikowski, “Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives,” European Heart Journal, vol. 34, no. 11, pp. 816–829, 2013. View at Publisher · View at Google Scholar
  28. V. Lahera, M. Goicoechea, S. G. De Vinuesa et al., “Oxidative stress in uremia: the role of anemia correction,” Journal of the American Society of Nephrology, vol. 17, no. 12, supplement 3, pp. S174–S177, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. D. S. Silverberg, D. Wexler, A. Iaina, and D. Schwartz, “The role of correction of anaemia in patients with congestive heart failure: a short review,” European Journal of Heart Failure, vol. 10, no. 9, pp. 819–823, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Bolignano, V. Donato, G. Coppolino et al., “Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage,” American Journal of Kidney Diseases, vol. 52, no. 3, pp. 595–605, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Link, R. Tirosh, A. Pinson, and C. Hershko, “Role of iron in the potentiation of anthracycline cardiotoxicity; identification of heart cell mitochondria as a major site of iron-anthracycline interaction,” Journal of Laboratory and Clinical Medicine, vol. 127, no. 3, pp. 272–278, 1996. View at Google Scholar · View at Scopus
  32. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity,” Pharmacological Reviews, vol. 56, no. 2, pp. 185–229, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. X. Xu, H. L. Persson, and D. R. Richardson, “Molecular pharmacology of the interaction of anthracyclines with iron,” Molecular Pharmacology, vol. 68, no. 2, pp. 261–271, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. S. D. Anker, J. C. Colet, G. Filippatos et al., “Ferric carboxymaltose in patients with heart failure and iron deficiency,” The New England Journal of Medicine, vol. 361, no. 25, pp. 2436–2448, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. C. J. Miranda, H. Makui, R. J. Soares et al., “Hfe deficiency increases susceptibility to cardiotoxicity and exacerbates changes in iron metabolism induced by doxorubicin,” Blood, vol. 102, no. 7, pp. 2574–2580, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. G. S. Panjrath, V. Patel, C. I. Valdiviezo, N. Narula, J. Narula, and D. Jain, “Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model,” Journal of the American College of Cardiology, vol. 49, no. 25, pp. 2457–2464, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Geisser and S. Burckhardt, “The pharmacokinetics and pharmacodynamics of iron preparations,” Pharmaceutics, vol. 3, no. 1, pp. 12–33, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. J. E. Toblli, G. Cao, L. Olivieri, and M. Angerosa, “Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds,” Nephrology, Dialysis, Transplantation, vol. 25, no. 11, pp. 3631–3640, 2010. View at Google Scholar · View at Scopus